Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | GAA | P10253 | 1/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22995757 | 0.96 | TSHR (0.46) | TSHRALDH1A1KMT2AGAAHPGD | |
| SCHEMBL20859051 | 0.94 | TSHR (0.48) | TSHRALDH1A1KMT2AGAAHPGD | |
| SCHEMBL19309616 | 0.91 | TSHR (0.46) | TSHRALDH1A1KMT2AGAAHPGD | |
| SCHEMBL46366 | 0.87 | LMNA (0.33) | TSHRALDH1A1HPGDLMNA | |
| SCHEMBL16093790 | 0.82 | TSHR (0.37) | TSHRALDH1A1 | |
| SCHEMBL31569967 | 0.82 | TSHR (0.36) | TSHR | |
| SCHEMBL27179114 | 0.78 | TSHR (0.36) | TSHR | |
| SCHEMBL5328127 | 0.78 | GAA (0.30) | GAA | |
| SCHEMBL13276440 | 0.76 | KDM4E (0.33) | ALDH1A1GAAHPGD | |
| SCHEMBL60409 | 0.76 | KDM4E (0.33) | ALDH1A1GAAHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | Epizyme, Inc. (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | Epizyme, Inc. | 2019-04-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10800743-B2 | Arginine methyltransferase inhibitors and uses thereof | PRMT1, PRMT3, PRMT5 | TSHR 3035/4885ALDH1A1 686/4885KMT2A 65/4885 |
| US-20190100496-A1 | ARGININE METHYLTRANSFERASE INHIBITORS AND USES THEREOF | PRMT1, PRMT3, PRMT5 | TSHR 3035/4885ALDH1A1 686/4885KMT2A 65/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.